Business
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business
About this update from Krystal Biotech, Inc.
[{"type":"image","alt":"Krystal Biotech, Inc.","displaySize":"","headline":null,"caption":"Krystal Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TkRG8dSXzhB4mkjEQnY_8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/65807d69171535c646e8328b9e91b8eb","width":300,"height":56}},"lazy":false},{"type":"text","content":"$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch","length":73,"tagName":"p"},{"type":"text","content":"FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD","length":122,"tagName":"p"},{"type":"text","content":"Strong balance sheet, ending the quarter with $955.9 million in cash and investments","length":84,"tagName":"p"},{"type":"text","content":"PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update.","length":225,"tagName":"p"},{"type":"text","content":"“In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “As we work toward our goal of launching multiple products and treating more than 10,000 patients living with rare diseases by the end of 2030, our recent cystic fibrosis readout further reinforces the versatility of our platform in high-turnover epithelial tissues. We believe we are still in the early stages of unlocking the transformational potential of our redosable HSV-1-based gene delivery platform, and we look forward to multiple registrational study readouts ahead across our rare disease pipeline.”","length":786,"tagName":"p"},{"type":"text","content":"VYJUVEK® (beremagene geperpavec-svdt, or B-VEC)for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)","length":107,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company recorded $107.1 million and $389.1 million in VYJUVEK net produc...